Abstract:Iodine-131‑labeled monoiodohypericin (131I‑Hyp) is a necrosis avid compound used as a complementary anticancer agent. Herein, the biodistribution in rats with re-perfused partial liver infarction (RPLI) was used to estimate its human internal radiation dosimetry. Iodine-123‑labeled monoiodohypericin (123I-Hyp) as a safer surrogate for 131I-Hyp was prepared with iodogen as oxidant. Determination of radiochemical yield and purification was performed by high performance liquid chromatography (HPLC). To control aggregation, the formulation was macroscopically and microscopically examined. Biodistribution of 123I-Hyp was studied in RPLI rats (n=18) at 4, 24 and 48 h post-injection. Tissue gamma counting (TGC), autoradiography and histology were performed. Dosimetry of 131I-Hyp in hepatic necrosis and in normal human organs was estimated using biodistribution data of 123I-Hyp, the Organ Level Internal Dose Assessment/Exponential Modeling (OLINDA/EXM®), a sphere model and male and female phantoms. A radiochemical yield of 95% was achieved in labeling of 123I-Hyp with a radiochemical purity of 99% after HPLC purification. In the Hyp added formulation, no macroscopic but minimal microscopic aggregation was observed. By TGC, selective accumulation in hepatic infarction and low uptake in viable liver of 123I‑Hyp/Hyp were detected, as confirmed by autoradiography and histology. Significantly higher doses of 131I-Hyp were delivered to necrotic (276‑93,600 mGy/MBq) than to viable (4.2 mGy/MBq) liver (P<0.05). In normal organs, 123I‑Hyp was eliminated within 24 h except for relatively high levels in the lungs and thyroid. Hepatobiliary elimination was a major pathway of 123I-Hyp causing high activity in the intestines. For both genders, dosimetry showed the longest residence time of 131I-Hyp in the remainder, followed by the lungs, intestines and thyroid. The highest absorbed radiation dose was seen in necrotic tissues and the shortest residence times and lowest absorbed radiation dose were found in the brain. 131I-Hyp selectively delivers higher radiation dose to necrosis compared with the rest of the body. Among normal organs, thyroids, lungs and intestines receive considerable radiation dose, which deserves cautious attention in developing this anticancer approach.

Evaluation of hypericin: effect of aggregation on targeting biodistribution

The impact of aggregation on the biodistribution of hypericin

Targetability and biodistribution of radioiodinated hypericin: comparison between microdosing and carrier-added preparations

Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation

Biodistribution and radiation dosimetry of radioiodinated hypericin as a cancer therapeutic

Biodistribution and anti-tumor efficacy of intratumorally injected necrosis-avid theranostic agent radioiodinated hypericin in rodent tumor models

First Preclinical Evaluation of Mono-[ 123 I]iodohypericin As a Necrosis-Avid Tracer Agent

A Model In Vitro Study Using Hypericin: Tumor-Versus Necrosis-Targeting Property and Possible Mechanisms

Sodium cholate, a solubilizing agent for the necrosis avid radioiodinated hypericin in rabbits with acute myocardial infarction

Hypericin as a marker for determination of tissue viability after intratumoral ethanol injection in a murine liver tumor model

Preparation and Biodistribution of Tumor Hypoxia Imaging Agents With Different Charges

Enhanced Retention and Cellular Uptake of Nanoparticles in Tumors by Controlling Their Aggregation Behavior.

Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy

Preparation and validation of cyclodextrin-based excipients for radioiodinated hypericin applied in a targeted cancer radiotherapy

Synthesis and Evaluation of 131I-Skyrin as a Necrosis Avid Agent for Potential Targeted Radionuclide Therapy of Solid Tumors

Biodistribution of 99 Tcm O-labeled MAG3-2-nitroimidazole hypoxia imaging agents with different spacers in S180 scarcoma-bearing mice

Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model

Subcellular distribution of polyhydroxylated metallofullerene Gd@C 82(OH) 22 in different tissues of tumor-bearing mice

Design, preparation and pharmacodynamics of ICG-Fe(III) based HCPT nanocrystals against cancer

Naturally available hypericin undergoes electron transfer for type I photodynamic and photothermal synergistic therapy

Preparation and Preliminary Evaluate of 99Tcm-Hynic-nga Complexes for Hepatic Asialoglycoprotein Receptor Imaging